Skip to content
Review Open access

Tumor Biomarkers in Head and Neck Squamous Cell Carcinoma: From Etiology and Pathogenesis to Treatment Response—A Scoping Review

Aug 2026 · Biomedicines · Vol 14, pp. 1842 · 0 citations · 84 references
Medicine

TL;DR

A comprehensive literature search was performed to map the available evidence on tumor biomarkers in HNSCC and identified several promising candidates with the potential to be incorporated into clinical practice following further prospective validation and methodological standardization.

Abstract

Currently, the global incidence of head and neck squamous cell carcinoma (HNSCC) continues to increase, with a large proportion of cases being diagnosed at advanced stages. Conventional oncological treatments are often associated with poor quality of life, while the aggressive biological behavior of these tumors results in recurrence in approximately half of treated patients according to current evidence. The need for rapid, targeted diagnosis and personalized treatment has driven research toward the identification of tumor biomarkers with diagnostic, prognostic, and predictive value for treatment response. In this scoping review, we performed a comprehensive literature search to map the available evidence on tumor biomarkers in HNSCC. We identified a wide range of biomarkers, several of which exhibit overlapping roles, and classified them according to their genomic, proteomic, cytokine-related, tumor microenvironment, metabolic, and microbiota-associated characteristics. This scoping review also summarizes the current evidence regarding biomarkers involved in carcinogenesis, treatment response and therapy resistance, while highlighting their current level of clinical applicability. Although only a limited number of biomarkers have currently been implemented in routine clinical practice in head and neck cancers, the studies included in this review identified several promising candidates with the potential to be incorporated into clinical practice following further prospective validation and methodological standardization. Many additional biomarkers are still under investigation, opening new perspectives for future diagnostic and therapeutic targets and supporting the development of personalized multimodal treatment strategies for patients with HNSCC.

Read PDF

Similar papers

Conference Open access 2026

Pathogenesis and research progress of head and neck squamous cell carcinoma

As the most prevalent cancer within the head-neck area, squamous cell carcinoma (HNSCC) makes up approximately 90% of all instances in this region. It is marked by a considerable probability of local re-occurrence, wide-spread metastasis to cervical lymph nodes, and typically poor overall survival rates. The progressio...

Boxin Chen · 0 citations
Review Open access 2026

Advancing Precision Oncology in the USA: A Literature Review of EGFR, MYC, and RAS Alterations in Head and Neck Cancers

Head and neck cancers (HNCs) constitute a diverse group of malignancies characterized by complex molecular alterations that contribute to tumor initiation, progression, therapeutic resistance, and clinical heterogeneity. In the era of precision oncology in the United States, a comprehensive understanding of key oncogen...

Yinemili Castro Oropeza, Ameera Qaddo, Dosapati Komala Preethi et al. · 0 citations
Review Oct 2026

Liquid biopsy in head and neck tumors: novel approaches and clinical applications.

Head and neck cancers (HNCs) represent one of the most prevalent and lethal types of cancer, accounting for 4.7% of annual cancer new cases and 4.9% of cancer-related mortalities. These high prevalence and mortality rates have positioned HNCs as a global health issue. Despite advances in disease treatment methods, the...

A. Yumashev, S. Amonov, Aisher Soliyev et al. · 0 citations
Open access Sep 2026

Tumor genomic alterations and their exploratory association with treatment response in recurrent head and neck cancer patients

While the genetic landscape of treatment-naïve head and neck squamous cell carcinoma (HNSCC) is well characterized, the molecular features of recurrent disease remain less defined. We investigated the genetic alterations in recurrent HNSCC and their associations with overall survival (OS), progression-free survival...

Olive Beyer, Andrey Loginov, D. Arons et al. · 0 citations
#data science Review Open access Oct 2026

The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review

Intratumor heterogeneity (ITH), the coexistence of diverse subclones within a single tumor, may pose a major challenge to effective chemotherapy in breast cancer. This cellular diversity contributes to treatment failure, residual disease, and early relapse by enabling tumor adaptation and therapeutic resistance. Althou...

Aria Dianati, Andre Dekker, A. Wesselius et al. · 0 citations
Open access Sep 2026

Dissociated response to immune checkpoint inhibition in head and neck squamous cell carcinoma is common and exhibits distinct clinical outcomes.

Immune checkpoint inhibition (ICI) constitutes the first-line therapy for relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) despite low response rates. Some patients treated with ICI experience dissociated response (DR), the co-existence of responding and progression lesions. DR prevalence and prognosti...

Alice N. Weaver, S. Keysar, Aarti Dureja et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.